<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzocaine, butamben, and tetracaine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzocaine, butamben, and tetracaine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Benzocaine, butamben, and tetracaine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11587" href="/d/html/11587.html" rel="external">see "Benzocaine, butamben, and tetracaine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3033396"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cetacaine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3033493"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F3033519"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4d03976-2034-4617-b713-0f3aeaa4bab2">Topical anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Apply 200 mg (~<sup>1</sup>/<sub>4</sub> to <sup>1</sup>/<sub>2</sub> inch); application of &gt;400 mg (&gt;1 inch) is contraindicated</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid: Apply 200 mg (~0.2 mL); application of &gt;400 mg (~0.4 mL) is contraindicated</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: Apply for ≤1 second; use of sprays &gt;2 seconds is contraindicated. <b>Note:</b> Spray provides ~200 mg/second</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992133"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989353"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F3033520"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Dose reduction is suggested; refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F3033518"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Dose has not been established; dose reduction is suggested</p></div>
<div class="block dorp drugH1Div" id="F51073535"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073536"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F3033501"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Also see Benzocaine and Tetracaine monographs.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Contact dermatitis (eg, erythema, local oozing, localized vesiculation, pruritus), eschar, xeroderma</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis (rare), hypersensitivity reaction (rare)</p></div>
<div class="block coi drugH1Div" id="F3033497"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to benzocaine, butamben, tetracaine, or any component of the formulation; ophthalmic use; cholinesterase deficiencies; application to large areas of denuded or inflamed tissue; administration in excess of product labeling; administration via injection; application under dentures or cotton rolls; children &lt;2 years of age</p></div>
<div class="block war drugH1Div" id="F3033498"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reaction: Hypersensitivity reactions, including anaphylaxis, may occur (rare). Localized reactions, including erythema, pruritus, vesiculation, and eschar, may occur; most commonly following prolonged or repeated use. Discontinue if rash, urticaria, edema, or other allergic response develop at application site. Prolonged use should only be done under continual medical supervision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients; dose adjustment is suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; dose adjustment is suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; dose adjustment is suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in very young patients (contraindicated in children &lt;2 years of age); dose adjustment is suggested.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For topical use only. Use under dentures or cotton rolls is contraindicated; retention of active ingredients may cause escharotic effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to cover the skin following application.</p></div>
<div class="block foc drugH1Div" id="F3033523"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Aerosol, Spray, Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (5g, 20 g) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (32 g)</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid, External:</p>
<p style="text-indent:-2em;margin-left:4em;">Cetacaine: Benzocaine 14%, butamben 2%, and tetracaine hydrochloride 2% (14 g, 30 g) [contains benzalkonium chloride]</p></div>
<div class="block geq drugH1Div" id="F3033491"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26597083"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Cetacaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2-14% (per gram): $14.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Cetacaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2-14% (per gram): $2.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F3033521"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Avoid application to large areas of broken skin. When possible, apply to clean, dry area; however, tissue need not be dried prior to application.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Gel: Spread thinly and evenly directly over application area where pain control is desired using a cotton swab.</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid: Apply with cotton or brush applicator or directly onto tissue; do not hold applicator in position for prolonged periods of time. Discard all applicators after use. Refer to manufacturer’s labeling for additional detailed information.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Apply directly to the site where pain or gag control is desired for procedure (ear, nose, mouth, pharynx, larynx, trachea, bronchi, esophagus, vagina, or rectum).</p></div>
<div class="block admp drugH1Div" id="F52614162"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Avoid application to large areas of broken skin, especially in children. When possible, apply to clean, dry area; however, tissue need not be dried prior to application.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Apply directly to the site where pain or gag control is desired for procedure (ear, nose, mouth, pharynx, larynx, trachea, bronchi, esophagus, vagina, or rectum).</p>
<p style="text-indent:-2em;margin-left:2em;">Gel: Spread thinly and evenly over application area using a cotton swab.</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid: Apply with cotton applicator or directly onto tissue; do not hold applicator in position for prolonged periods of time.</p></div>
<div class="block use drugH1Div" id="F3033494"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Topical anesthesia: </b>Topical anesthetic to control pain in surgical or endoscopic procedures, or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus (may also be used for vaginal or rectal procedure, when feasible); anesthetic for accessible mucous membranes except for the eyes; to control pain or gagging (spray only)</p></div>
<div class="block mst drugH1Div" id="F54873941"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Benzocaine, when used in pediatric patients &lt;2 years of age for teething or pharyngitis, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of methemoglobinemia (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298838"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218303"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F3033495"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Safety has not been established; use is not recommended during early pregnancy unless the potential benefits outweigh the risks.</p></div>
<div class="block mop drugH1Div" id="F3882051"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Monitor patients for signs and symptoms of methemoglobinemia such as pallor, cyanosis, nausea, muscle weakness, dizziness, confusion, agitation, dyspnea and tachycardia. The classical clinical finding of methemoglobinemia is chocolate brown-colored arterial blood. However, suspected cases should be confirmed by co-oximetry, which yields a direct and accurate measure of methemoglobin levels. Standard pulse oximetry readings or arterial blood gas values are not reliable. Clinically significant methemoglobinemia requires immediate treatment.</p></div>
<div class="block pha drugH1Div" id="F3033509"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversible blockage of initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions</p></div>
<div class="block phk drugH1Div" id="F3033511"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Also see individual monographs for Benzocaine and Tetracaine.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~30 seconds</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Plasma via hydrolysis by cholinesterase to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Cetacaine (benzocaine/butamben/tetracaine) gel [prescribing information]. Pennsauken, NJ: Cetylite Industries Inc; October 2018.</div>
</li>
<li>
<div class="reference">
                  Cetacaine (benzocaine/butamben/tetracaine) spray and liquid [prescribing information]. Pennsauken, NJ: Cetylite Industries Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/benzocaine-butamben-and-tetracaine-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8818 Version 118.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
